Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative
09:05am, Wednesday, 28'th Apr 2021
SAN DIEGO--(BUSINESS WIRE)--Illumina announced commitment of $60 million to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation.
How Illumina's Q1 Results Delighted Investors
06:04am, Wednesday, 28'th Apr 2021
Nearly everything went right for the genomic sequencing pioneer.
Illumina, Inc. (ILMN) CEO Francis deSouza on Q1 2021 Results - Earnings Call Transcript
09:51pm, Tuesday, 27'th Apr 2021
Illumina, Inc. (ILMN) CEO Francis deSouza on Q1 2021 Results - Earnings Call Transcript
Illumina (ILMN) Q1 Earnings and Revenues Top Estimates
06:02pm, Tuesday, 27'th Apr 2021
Illumina (ILMN) delivered earnings and revenue surprises of 38.97% and 0.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Illumina (ILMN) This Earnings Season?
09:01am, Monday, 26'th Apr 2021
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Healthcare Stocks About to be Bolstered by Biden's American Rescue Plan
06:35am, Saturday, 24'th Apr 2021
The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit.
Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
04:05pm, Thursday, 22'nd Apr 2021
SAN DIEGO--(BUSINESS WIRE)--Illumina and Kartos Therapeutics announce a new partnership to co-develop a TP53 CDx based on the TruSight™ Oncology 500 (TSO 500) assay.
Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
06:30am, Tuesday, 20'th Apr 2021
SAN DIEGO--(BUSINESS WIRE)--Illumina disagrees with the European Commission's Directorate-General for Competition's decision to review Illumina's acquisition of GRAIL.
3 Biden Healthcare Stocks to Watch
06:42am, Saturday, 17'th Apr 2021
The administration's focus on the Affordable Care Act, access to healthcare, and research may accelerate growth for these three stocks.
Is Illumina Still a Buy Without the GRAIL Acquisition?
08:54am, Thursday, 15'th Apr 2021
Sometimes the most carefully laid plans hit unforeseen snags.
The Big Questions for Illumina After Its Q1 Sneak Peek and 2021 Guidance
07:01am, Wednesday, 14'th Apr 2021
The gene sequencing giant has a couple of key challenges going forward.
Illumina Named One of Singapore's Best Employers
08:38pm, Monday, 12'th Apr 2021
SINGAPORE--(BUSINESS WIRE)--Illumina Named One of Singapore's Best Employers
This Unstoppable Stock Doesn't Pay a Dividend Yet, but It Could
06:32am, Friday, 09'th Apr 2021
This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.
Could Illumina's Quest to Acquire GRAIL Fail?
06:04am, Friday, 09'th Apr 2021
The chances are certainly higher now that the deal won't happen.
Illumina CEO says GRAIL deal is good for competition
03:19pm, Thursday, 08'th Apr 2021
The chief executive of life sciences company Illumina argued Thursday his company's deal to buy back GRAIL would lead to cheaper cancer tests rather than potentially pushing up prices as the governmen
